StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera Genetic Testing Services by Quarter

Genetic Testing Services — Current Contract Liability ($M) [legacy through Q3 2025] ($M)

Natera Genetic Testing Services: $19.6M in Q3 2025, up 36.1% from a year earlier. That is the highest of the 11 quarters on record here.

Latest, Q3 2025
19.6
Period ended Sep 30, 2025
Change on a year earlier
+36.1%
14.4 in Q3 2024
History
11 quarters
Since Q4 2022
Sources
11
Documents cited below

Where the Q3 2025 figure comes from

Source: Form 10-Q (2025-11-07) ↗

Reported in Form 10-K/10-Q Note — Revenue Recognition (2022–2025Q3).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGenetic Testing Services — Current Contract Liability ($M) [legacy through Q3 2025] ($M)Year on yearSource
Q3 2025Sep 30, 202519.6+36.1%Form 10-Q (2025-11-07) ↗
Q2 2025Jun 30, 202519.4+31.1%Form 10-Q (2025-08-08) ↗
Q1 2025Mar 31, 202518.6+24.8%Form 10-Q (2025-05-09) ↗
Q3 2024Sep 30, 202414.4+12.5%Form 10-Q (2024-11-12) ↗
Q2 2024Jun 30, 202414.8+10.4%Form 10-Q (2024-08-09) ↗
Q1 2024Mar 31, 202414.9+4.9%Form 10-Q (2024-05-10) ↗
Q4 2023Dec 31, 202313.7+28.0%Form 10-K (2024-02-29) ↗
Q3 2023Sep 30, 202312.8–Form 10-Q (2023-11-09) ↗
Q2 2023Jun 30, 202313.4–Form 10-Q (2023-08-04) ↗
Q1 2023Mar 31, 202314.2–Form 10-Q (2023-05-10) ↗
Q4 2022Dec 31, 202210.7–Form 10-K (2023-03-01) ↗

Cite this data

StockData. (2026). Natera Genetic Testing Services ($M), quarterly Q4 2022–Q3 2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/contract-liab-genetic-testing-current

See every metric in the Natera KPI table. Data updated Nov 2, 2026.